Literature DB >> 27923614

Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma.

Shengyu Huang1, Yong Xia1, Zhengqing Lei1, Qifei Zou2, Jun Li1, Tian Yang1, Kui Wang2, Zhenlin Yan1, Xuying Wan3, Feng Shen4.   

Abstract

BACKGROUND: The aim of this study was to explore the impact of antiviral therapy (AVT) on short- and long-term outcomes after rehepatectomy for patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). STUDY
DESIGN: We analyzed data from 583 consecutive patients who underwent rehepatectomy for intrahepatic recurrence of HBV-related HCC after initial hepatectomy, between 2006 and 2011 at the Eastern Hepatobiliary Surgery Hospital. Tumor re-recurrence, recurrence to death survival (RTDS), and overall survival (OS) were compared using the Kaplan-Meier method and log-rank test. The independent risk factors of prognoses were analyzed using the Cox proportional hazards model. Postoperative viral reactivation, surgical morbidity, and mortality were also observed.
RESULTS: Preoperative AVT reduced viral reactivation rate after rehepatectomy (5.8% for AVT patients, 16.3% and 16.6% for non-AVT patients with viral level ≤ or >2,000 IU/mL, respectively; p ≤ 0.028). Viral reactivation and non-AVT were independent risk factors of tumor re-recurrence (hazard ratios 1.446 and 1.778, respectively), RTDS (1.691 and 2.457, respectively), and OS (1.781 and 1.857, respectively). The AVT improved long-term outcomes as compared with non-AVT with a viral level of ≤ or >2,000 IU/mL (5-year re-recurrence rate: 69% vs 81% vs 96%, respectively; 5-year RTDS rate: 47% vs 27% vs 17%, respectively; all p ≤ 0.016). Pre- plus postoperative AVT achieved a better 5-year OS rate than postoperative AVT alone (83% vs 60%; p = 0.045); there were insignificant differences in 5-year re-recurrence and RTDS rates (61% vs 77%, p = 0.102; 50% vs 44%, p = 0.395).
CONCLUSIONS: Preoperative AVT decreased viral reactivation rate, and AVT initiated either before or after rehepatectomy contributed to better long-term prognoses after rehepatectomy for recurrent HBV-related HCC. Copyright Â
© 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27923614     DOI: 10.1016/j.jamcollsurg.2016.11.009

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

1.  Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma.

Authors:  Zhenli Li; Geng Chen; Zhixiong Cai; Xiuqing Dong; Liman Qiu; Haipo Xu; Yongyi Zeng; Xiaolong Liu; Jingfeng Liu
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

Review 2.  Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions.

Authors:  Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

Review 3.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

4.  Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report.

Authors:  Kazuhiro Takahashi; Krishna G Putchakayala; Mohamed Safwan; Dean Y Kim
Journal:  World J Hepatol       Date:  2017-08-08

5.  Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas.

Authors:  Yanyan Wei; Yongxiang Yi; Chen Tao; Wei Ye; Wei Zhao
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

6.  Predictors of Spontaneous Rupture of Hepatocellular Carcinoma and Clinical Outcomes Following Hepatectomy.

Authors:  Yiran Chen; Deliang Guo; Xinyi Li; Chang Xu; Qian Zhu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.